Benzinga | May 28, 2021 07:56AM EDT

WBB Securities Downgrades Redhill Biopharma to Buy, Lowers Price Target to $16

WBB Securities analyst Steve Brozak downgrades Redhill Biopharma (NASDAQ:RDHL) from Strong Buy to Buy and lowers the price target from $17 to $16.